Product Update
-
Axio Biosolutions receives European CE Mark approval
The company’s advanced woundcare product – MaxioCel; sets eye on Europe and other international markets Funded by Ratan Tata’s UC…
Read More » -
GSK Consumer Healthcare launches Otrivin Breathe Clean
The product comes in in a contemporary aerosol spray format, providing a great user experience GSK Consumer Healthcare announced the…
Read More » -
Cipla partners with Premier Medical Corporation
Launches ‘CIPtest’ rapid antigen detection test for COVID-19 diagnosis Cipla has partnered with Premier Medical Corporation for commercialisation of the…
Read More » -
DermaAngel forays into the Indian market
Launches two variants of acne patch BenQ Materials Corp has forayed into the Indian market with the launch of acne…
Read More » -
Co-Diagnostics JV Receives Indian Regulatory Approval for Five Diagnostic Assays
Salt Lake City: Co-Diagnostics, Inc., Utah based molecular diagnostics company with a unique, patented platform for the development of molecular…
Read More » -
Now Cipla to sell Alvotech’s Adalimumab Biosimilar in Emerging Markets
Biopharmaceutical company Alvotech and Cipla Gulf, a wholly-owned subsidiary of the leading global pharmaceutical company Cipla Limited, today announced that…
Read More » -
Health Canada Approves Biocon & Mylan’s biosimilar Trastuzumab, Ogivri
Biocon Ltd. and Mylan N.V. today announced that Health Canada has approved Mylan’s Ogivri™(trastuzumab), a biosimilar to Herceptin ® 1…
Read More » -
Cipla receives final approval for generic version of Gilead Sciences’s Letairis
Cipla Limited and its subsidiary Cipla USA, Inc., (hereafter referred to as “Cipla”) announce receipt of final approval for the…
Read More » -
World’s First Generic Eribulin for Treatment of Metastatic Breast Cancer Launched in India
Emcure Pharmaceuticals, a leading integrated global pharmaceutical company from India, today, announced the launch of the world’s first generic version…
Read More » -
U.S. FDA Approves Mylan and Biocon’s Fulphila™ (pegfilgrastim-jmdb)
Mylan N.V. and Biocon Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved Mylan’s Fulphila™ (pegfilgrastim-jmbd),…
Read More »
